Your Drug Discovery Partner

Date: 28/05/2015

To
Deputy Manager
Dept. of Corporate Services,
Bombay Stock Exchange Limited
P J Towers, Dalal Street,
Fort, MUMBAI – 400001

Sub: Outcome of Board Meeting held on 28th May 2015-Reg.

Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 28th May 2015 and transacted following business:

1. Approved the Audited Financial Results for Quarter and year ending on 31st March, 2015

We are herewith attaching the results sheet and Auditor Report on Quarterly Audited Financial Results and year to date Audited Financial Results pursuant Clause 41 of Listing agreement.

This is for your record and reference.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Limi

M Kalyan Ram

Whole Time Directo

DIN: 02012580

Registered Office: #608, 6th Floor, Lingapur Complex, Himayath Nagar, Hyderabad - 500029, Telangana, INDIA. Telephone: +91 - 40 - 2789 0662 - 5; Fax: +91 - 40 - 2789 0669 Address of Preclinical Research Facility: Vivo Bio Tech Special Economic Zone, Survey No. 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, CIN No. L65993TG1987PLC007162

Your Drug Discovery Partner

| PAF | RT -1 | | | | | | | Rs. In Lakhs | |
|------|--|------------------------|---------------|------------|---------------|-----------|-----------------|---------------|--|
| _ | Audited Financial R | March 4 and 4 and 1000 | | | | | 72 - L | | |
| - | Audited Financial R | esults for the qu | arter and | l Year end | ed 31/03/2015 | | | | |
| 5. | .No. PARTICULARS | | QUARTER ENDED | | | | | | |
| - | | 31.03.20 | | 31.12.2014 | 31.03.20 | 14 21 | 7EAR 03.2015 | ENDED | |
| - | 1 Income from Operations | Audite | d | Unaudited | d Audited | | | 31.03.2014 | |
| | a) Net Sales/ Income from Operations | | | | | Addit | eu | Audited | |
| - | b) Other Operating Income | 59 | 8.38 | 464. | 40 40 | 5.90 | 1.770.00 | | |
| | Total Income from operations | - | 0.00 | 0. | 00 | 0.00 | 1,778.85 | 1612 | |
| | 2 Expenses | 598 | 8.38 | 464. | | | 0.00 | 0 | |
| - | a. Increase/(decrease) in stock in trade and WIP | | | | | | 1,778.85 | 1612. | |
| _ | consumption of Kaw materials | | 3,80) | 0.0 | 00 -26 | .31 | (438.00) | | |
| | c. Purchase of traded goods | | 0.93 | 94.7 | 700 | .02 | 745.06 | -26. | |
| | d. Employees Cost | | 0.00 | 0.0 | 0 | .00 | 0.00 | 294. | |
| | e Depreciation . | | 41 | 104,0 | | | 293.73 | 0.0 | |
| | I. Other Expenditure | 174 | .55 | 48.2 | | | 304.64 | 222.8 | |
| _ | I.Administrative Expenditure | | | | - | | 304.04 | 156.2 | |
| | g. Total | 259 | _ | 216,11 | 301. | 94 | 897.50 | | |
| 3 | Profit/loss from Operations before other income, finance cost and exceptions items(1.2) | 602, | 83 | 463.19 | | _ | 802.94 | 946.1 | |
| 4 | Cost and exceptions items(1-2) Other income | 71. | 45) | 2007 | | 1, | 502.34 | 1593.8 | |
| | Profit/(loss) from O-dia | 31.8 | | 1.21 | 0. | | (24.09) | 18.70 | |
| 5 | Profit/(loss) from Ordinary activities before finance costs and exceptional items(3+4) | 54.0 | - | 20.92 | 29,0 | 14 | 94.75 | 88.29 | |
| 6 | Finance costs | 27.4 | | 22.13 | 35.9 | 5 | 70.55 | 00.2 | |
| 7 | Profit/(loss) from Ordinary activities after finance costs but before exceptional items(f) | 19_1 | 16 | 11.34 | 19.3 | | 70.67 | 106, 99 | |
| 8 | | 0.3 | | | 19.5 | | 51.40 | 39.29 | |
| | Exceptional items | 8.2 | _ | 10.79 | 16.5 | 9 | 19.27 | (7.50 | |
| 9 | THE RECORD SECTION AND ADDRESS OF THE PERSON ADDRESS OF THE PERSON AND ADDRESS OF THE PERSON ADDRESS OF THE PERSON AND ADDRESS OF THE PERSON ADDRESS OF THE PERSON ADDRESS OF THE PERSON AND ADDRESS OF THE PERSON ADDRESS OF THE | 0,0 | 00 | 0.00 | 0.00 | | 0.00 | 67.70 | |
| 10 | Profit/Loss from Ordinary Activities before tax(7-8) | 0.2 | | | | | | 0.00 | |
| 11 | - Aprilae | 8.27 | | 10.79 | 16.59 | 4 | 19.27 | (7.50 | |
| 12 | Net Profit/Loss from Ordinary Activities after Tax(9-10) | (32.93 | - | 3,24 | 27.17 | | 27.01) | 67.70 | |
| 13 | tens (Net of Tay exponent p | 41.18 | | 7.55 | -10.58 | | 16.28 | 38.33 | |
| 14 | Loss for the Period(11-12) | 0,0 41.18 | | 0.00 | 0.00 | | 0.00 | 29.37 | |
| - | Paid Up Share Capital(Face Value of Rs.10/-each) | 935.05 | | 7.55 | -10.58 | 4 | 6.28 | 0.00 29,37 | |
| 15 | Reserves Excluding Revaluation Reserves as per Balance sheet of previous accounting year | 333,03 | | 935.05 | 935.05 | 93 | 5.05 | 935.05 | |
| 6.i | Earning Per Share(EPS)(Before Extraordinary items) | 0.00 | 0 | 0.00 | 0.00 | | | 755.63 | |
| | a)Basic | | | | 0.00 | | 0.00 | 0.00 | |
| | b)Diluted | 0,44 | | 0.08 | -0.11 | | | | |
| 5,ii | Earning Per Share(EPS)(After Extraordinary items) | 0,44 | | 0.08 | -0.11 | | 0.49 | 0.31 | |
| | a) Basic | | | | -0.11 | (| 0.49 | 0.31 | |
| | b) Diluted | 0.44 | | 0.08 | -0.11 | | | | |
| -11- | Select Information for the Qtr and year ended on 31/03/2015 | 0,44 | | 0.08 | -0.11 | | .49 | 0.31 | |
| | | | | | 0.11 | | .49 | 0.31 | |
| | Particulars of Shareholding | | | | T | | | | |
| | Public Shareholding | | | | _ | | - 6 | | |
| | Number of Shares | | | | | | _ | | |
| | Percentage of Shareholding | 30,43,970 | 29,2 | 6,437 | 29,26,437 | 30,43,9 | 70 | | |
| | Promoters and Promoter Group Shareholding | 32.55% | 3 | 1.30% | 31.30% | | | 29,26,437 | |
| | a) Fledged/Encumbered | | | | -100 | 32,5 | 5"/4 | 31,30% | |
| 1 | Number of Shares | | | | | | | | |
| - | Percentage of Shares | 0 | | 0 | 0 | | | | |
| 1 | (as a % of the total shareholding of promoter and | | | | | | 0 | 0 | |
| | Percentage of Shares | 0 | | | 17 | | | 11 | |
| (| as a % of the total sharecapital of the company) | | | 0 | 0 | | 0 | Na | |
| 147 | 7. Von-Encumpered | 0 | | 0 | | | | 10 | |
| 1 | Number of Shares | | | - | 0 | | 0 | ()=1 | |
| :1- | Percentage of Sharps | 63,06,550 | 64,24, | 083 | 64,24,083 | 62000 | | N> | |
| (4) | is a % of the total shareholding or | | | | 1,003 | 63,06,550 |) | 64,24,083 | |
| - | and the state of t | 1000 | 2 | | | | | | |
| | Percentage of Shares s a % of the total sharecapital of the company) | 100% | 1 | 00% | 100% | 1009 | % | 100% | |
| | | | | | | | 1 | 11011% | |

Registered Office: #608, 6th Floor, Lingapur Complex, Himayath Nagar, Hyderabad - 500029, Telangana, INDIA. Telephone: +91 - 40 - 2789 0662 - 5; Fax: +91 - 40 - 2789 0669 Address of Preclinical Research Facility: Vivo Bio Tech Special Economic Zone, Survey No. 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, Telangana, INDIA. Email: contact@vivobio.com Website: www.vivobio.com

Your Drug Discovery Partner

Notes

- 1 The above results were reviwed by the Audit committee and approved by the Board of Directors in their meeting
- 2 The quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2015 and the published year-to-date figures up to December 31, 2014, being the date of the end of the third quarter of the current financial year,
- 3 Financials are prepared in accordance with generally accepted accounting principles and accounting standards
- 4 Figures of previous year/ period have been regrouped and reclassified or recast or re-arranged where ever considered necessary 5 Status of complaints from the investors during the quarter ended 31st March, 2015

Pending-0 Nos Complaints Received -3 Nos., Complaints resolved - 3 Nos., Complaints lying upresolved - 0 No. 6 The company Operates in Only one Segment

Place: Hyderabad

Date: 28th May 2015

For Vivo Bio Tech Limited

M Kalyan Ram

Whole Time Director DIN: 02012580

Registered Office: #608, 6th Floor, Lingapur Complex, Himayath Nagar, Hyderabad - 500029, Telangana, INDIA. Telephone: +91 - 40 - 2789 0662 - 5; Fax: +91 - 40 - 2789 0669 Address of Preclinical Research Facility: Vivo Bio Tech Special Economic Zone, Survey No. 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, Telangana, INDIA. Email: contact@vivobio.com Website: www.vivobio.com

CIN No. L65993TG1987PLC007163


Your Drug Discovery Partner

| | Statement of Assets and Liab | In Rupees | | | |
|---|------------------------------------|---------------------------------------|---------------------------|--|--|
| | | As AT 31/03/2015 | As AT 31/03/2014 Audited | | |
| | Particulars | Audited | | | |
| Α | EQUITY AND LIABILITIES | | | | |
| 1 | Shareholders' funds | n . | | | |
| | a) Share Capital | 935,05,200 | 935,05,200 | | |
| | b) Reserves and Surplus | (17,73,833) | (82,16,439 | | |
| | Sub-total -Shareholders' Funds | 917,31,367 | 852,88,76 | | |
| 2 | Non-Current Liabilities | | | | |
| | a)Long Term borrowings | 265,96,425 | 354,59,77 | | |
| | b) Defffered tax liabilites | 111,88,502 | 142,56,73 | | |
| | c)Other Long term liabilities | # | 1 | | |
| | d) Long term provisions | 16,01,041 | 12,97,40 | | |
| | Sub-total -Non-Current Liabilities | 393,85,968 | 510,13,92 | | |
| 3 | Current Liabilities | | | | |
| | a) Short-term Borrowings | 303,23,862 | 307,69,84 | | |
| | b) Trade Payables | 685,35,030 | 854,71,62 | | |
| | c)Other Curren Liabilities | 1371,87,753 | 1027,56,37 | | |
| | d) Short Term provisions | 471,31,169 | 451,47,78 | | |
| | Sub-total -Current Liabilities | 2831,77,815 | 2641,45,62 | | |
| | | | | | |
| | TOTAL-EQUITY AND LIABILITIES | 4142,95,151 | 4004,48,30 | | |
| В | ASSETS | | | | |
| 4 | Non-Current Assets | | | | |
| | a)Fixed Assets | | | | |
| | i)Tangible Assets | 1466,42,453 | 1479,30,48 | | |
| | ii) Intangible Assets | 490,14,986 | 567,20,46 | | |
| | (iii) Capital Work-in-progress | 7,06,264 | | | |
| | b) Non-Current Investments | 2,00,000 | 13,71,87 | | |
| | e) Other non-current assets | 2,89,265 | 3,21,95 | | |
| | | , , , , , , , , , , , , , , , , , , , | | | |
| | Sub-total Non-Current Assets | 1968,52,967 | 2063,44,78 | | |
| 2 | Current Assets | | | | |
| | a) Inventories | 468,70,254 | 30,70,50 | | |
| | b) Trade Receivables | 430,80,514 | 430,46,51 | | |
| | c)Cash and cash equivalents | 1055,92,179 | 1123,59,46 | | |
| | d) short term loans and advances | 135,13,955 | 311,66,56 | | |
| | e) Other current assets | 83,85,282 | 44,60,47 | | |
| | Sub-Total Current Assets | 2174,42,184 | 1941,03,52 | | |
| - | TOTAL ASSETS | 4142,95,151 | 4004,48,30 | | |

Place: Hyderabad Date: 28th May 2015



Registered Office: #608, 6th Floor, Lingapur Complex, Himayath Nagar, Hyderabad - 500029, Telangana, INDIA. Telephone: +91 - 40 - 2789 0662 - 5; Fax: +91 - 40 - 2789 0669 Address of Preclinical Research Facility: Vivo Bio Tech Special Economic Zone, Survey No. 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, Telangana, INDIA. Email: contact@vivobio.com Website: www.vivobio.com



Tel.

: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax E-mail

: (91-40) 2339 2474

: pmurali.co@gmail.com info@pmurali.com

Website: www.pmurali.com

Auditor's Report on Quarterly Financial Results and Year to Date Financial Results of Vivo Bio tech Limited pursuant to the Clause 41 of the Listing Agreement

To,
The Board of Directors of **Vivo Bio tech Limited**

- We have audited the quarterly financial results of Vivo Bio tech Limited for the quarter ended March 31, 2015 and to the year to date financial results for the year ended March 31, 2015, attached herewith, being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement, except for the disclosures regarding Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2015 and the published year-to-date figures up to December 31, 2014, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The financial results for the quarter ended March 31, 2015 have been prepared on the basis of the financial results for the nine-month period ended December 31, 2014, the audited annual financial statements as at and for the year ended March 31, 2015, and the relevant requirements of Clause 41 of the Listing Agreement and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these Financial results based on our review of the financial results for the nine-month period ended December 31, 2014 prepared in accordance with the recognition measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the act, read with rule 7 of the companies(Accounts) Rules 2014 and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended March 31, 2015; and the relevant requirements of clause 41 of the listing agreement.
- 2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

3. In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date financial results:

a Abl &



Tel. : (9

: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax

: (91-40) 2339 2474

E-mail: pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

(i) are presented in accordance with the requirements of Clause 41 of the Listing agreement in this regard; and

- (ii) give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2015 as well as the year to date results for the period from April 1, 2014 to March 31, 2015.
- 4. Further, read with paragraph 1 above, we report that the figures for the quarter ended March 31, 2015 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2015 and the published year-to-date figures up to December 31, 2014, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated in paragraph 1 above, as required under Clause 41 (I)(d) of the Listing Agreement.
- 5. Further, read with paragraph 1 above, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For P. Murali & Co., Chartered Accountants Firm's Registration number: 007257S

P. Murali Mohana Rao

Partner M.No. 023412

Place: Hyderabad Date: 28/05/2015